HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
Theme 		Help

New: Introducing the Finviz Crypto Map

Learn More

KRRO

Korro Bio Inc

Last Close
Jul 15 • 04:00PM ET
12.66
Dollar change
-0.31
Percentage change
-2.35 		%
Healthcare • Biotechnology • USA • NASD
Peers: BEAM EDIT NTLA CRSP RGNX FDMT VYGR ARVN SGMO CRBU
 | Held by: VTI IWM VXF IWN VTWO IWC ITOT VHT AVSC RSSL
Scroll to Statements
IndexRUT P/E- EPS (ttm)-9.44 Insider Own41.54% Shs Outstand9.39M Perf Week-6.77%
Market Cap118.88M Forward P/E- EPS next Y-8.89 Insider Trans0.00% Shs Float5.49M Perf Month-9.44%
Enterprise Value49.12M PEG- EPS next Q-2.57 Inst Own70.42% Short Float18.38% Perf Quarter-1.86%
Income-87.41M P/S24.66 EPS this Y-0.98% Inst Trans5.15% Short Ratio7.44 Perf Half Y-64.10%
Sales4.82M P/B0.86 EPS next Y5.99% ROA-43.68% Short Interest1.01M Perf YTD-66.75%
Book/sh14.80 P/C1.03 EPS next 5Y-0.48% ROE-60.22% 52W High98.00 -87.08% Perf Year-72.39%
Cash/sh12.24 P/FCF- EPS past 3/5Y57.64% 21.83% ROIC-48.07% 52W Low10.29 23.03% Perf 3Y-73.21%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-45.55% -39.89% Gross Margin15.70% Volatility9.38% 8.46% Perf 5Y-97.79%
Dividend TTM- EV/Sales10.19 EPS Y/Y TTM75.25% Oper. Margin-1980.44% ATR (14)1.24 Perf 10Y-
Dividend Ex-Date- Quick Ratio9.41 Sales Y/Y TTM- Profit Margin-1813.13% RSI (14)46.59 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio9.41 EPS Q/Q-2.20% SMA20-1.09% Beta4.60 Target Price94.11
Payout- Debt/Eq0.33 Sales Q/Q- SMA50-7.97% Rel Volume0.97 Prev Close12.97
Employees104 LT Debt/Eq0.31 EarningsMay 07 AMC SMA200-59.36% Avg Volume135.55K Price12.66
IPOOct 03, 2019 Option/ShortNo / Yes EPS/Sales Surpr.3.56% 488.78% Trades Volume131,682 Change-2.35%
Date Action Analyst Rating Change Price Target Change
Apr-29-25Initiated Cantor Fitzgerald Overweight $74
Apr-16-25Initiated Chardan Capital Markets Buy $25
Jan-10-25Initiated Oppenheimer Outperform $155
Oct-21-24Initiated Raymond James Strong Buy $153
Aug-14-24Initiated William Blair Outperform $180
Mar-28-24Reiterated H.C. Wainwright Buy $100 → $115
Feb-27-24Initiated BMO Capital Markets Outperform $120
Dec-04-23Initiated H.C. Wainwright Buy $100
Nov-29-23Initiated RBC Capital Mkts Outperform $70
Nov-10-23Initiated Piper Sandler Overweight $180
Show Previous Ratings
May-14-25 04:05PM
Korro to Participate in Upcoming Investor Conferences
(GlobeNewswire) -9.26%
May-09-25 10:31AM
Korro Bio price target lowered to $53 from $130 at H.C. Wainwright
(TipRanks)
May-07-25 04:30PM
Korro Reports First Quarter 2025 Financial Results and Provides Business Updates
(GlobeNewswire) -5.85% +10.55%
Apr-01-25 07:30AM
Korro Appoints Biotech Industry Veteran, Loic Vincent, Ph.D., as Chief Scientific Officer
(GlobeNewswire) -8.39%
07:30AM
Korro Appoints Biotech Industry Veteran, Lo c Vincent, Ph.D., as Chief Scientific Officer
(GlobeNewswire)
06:18PM Loading…
Mar-28-25 06:18PM
Korro Bio: Promising Early Stage RNA Editing Company
(Seeking Alpha) -5.11%
Mar-18-25 07:00AM
Korro Reports Full Year 2024 Financial Results and Provides Business Updates
(GlobeNewswire)
Mar-17-25 07:26AM
FDA grants orphan drug status for Korro Bio's AATD therapy
(Pharmaceutical Business Review)
Mar-14-25 08:00AM
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
(GlobeNewswire)
Feb-26-25 08:00AM
Korro to Present at the TD Cowen 45th Annual Health Care Conference
(GlobeNewswire)
Jan-13-25 08:00AM
Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update
(GlobeNewswire) +8.20%
Jan-07-25 08:00AM
Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference
(GlobeNewswire) -7.23%
Dec-10-24 08:00AM
CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors
(GlobeNewswire)
Nov-21-24 04:01PM
Korro to Participate in Upcoming Investor Conferences
(GlobeNewswire) +7.70%
07:30AM
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency
(GlobeNewswire)
08:00AM Loading…
Nov-14-24 08:00AM
Korro to Present at the Jefferies London Healthcare Conference
(GlobeNewswire) -9.65%
Nov-12-24 04:05PM
Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates
(GlobeNewswire) -11.37% -15.55%
Nov-04-24 07:25AM
Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board
(GlobeNewswire)
Oct-21-24 04:15PM
Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.
(Investor's Business Daily) -5.22% -7.70%
Oct-16-24 04:20PM
Wave Life Sciences Just Edited RNA. Why Its Key Rival, Korro Bio, Skyrocketed.
(Investor's Business Daily) +93.66%
Sep-30-24 08:00AM
Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society
(GlobeNewswire)
Sep-16-24 08:00AM
Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates
(GlobeNewswire)
Sep-10-24 08:00AM
Korro to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Aug-28-24 08:00AM
Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors
(GlobeNewswire)
Aug-27-24 08:00AM
Korro to Participate in Upcoming September Investor and Scientific Conferences
(GlobeNewswire)
Aug-13-24 04:01PM
Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates
(GlobeNewswire) +9.21%
Jul-01-24 08:00AM
Korro Joins the Russell 2000 , Russell 3000 , and Russell Microcap Indexes
(GlobeNewswire)
Jun-25-24 12:53PM
KRRO Stock Earnings: Korro Bio Beats EPS for Q4 2023
(InvestorPlace)
May-30-24 04:01PM
Korro to Participate in Upcoming June Investor and Scientific Conferences
(GlobeNewswire)
May-20-24 02:30PM
Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference
(GlobeNewswire)
10:55PM Loading…
May-14-24 10:55PM
KRRO Stock Earnings: Korro Bio Beats EPS for Q1 2024
(InvestorPlace) +5.43%
04:01PM
Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer
(GlobeNewswire)
Apr-18-24 08:30AM
Korro Announces $70 Million Private Placement
(GlobeNewswire)
Apr-01-24 04:01PM
Korro to Participate in Upcoming Investor Conferences
(GlobeNewswire) -7.90%
Mar-26-24 04:01PM
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress
(GlobeNewswire) +18.43%
Feb-27-24 09:55AM
Wall Street Analysts Believe Korro Bio, Inc. (KRRO) Could Rally 86.94%: Here's is How to Trade
(Zacks) -6.08%
08:00AM
Korro to Present at the TD Cowen 44th Annual Health Care Conference
(GlobeNewswire)
Feb-09-24 09:55AM
Does Korro Bio, Inc. (KRRO) Have the Potential to Rally 59.66% as Wall Street Analysts Expect?
(Zacks)
Jan-18-24 08:00AM
Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio
(GlobeNewswire) -5.98%
Jan-04-24 08:00AM
Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference
(GlobeNewswire)
Dec-07-23 08:00AM
Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
(GlobeNewswire) -14.67%
Nov-28-23 08:00AM
Korro Bio Appoints Dr. Rachel Meyers to Board of Directors
(GlobeNewswire) +6.45%
Nov-03-23 03:31PM
UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
(GlobeNewswire) +5.94%
12:19PM
Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
(GlobeNewswire)
Aug-10-23 04:01PM
Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results
(Business Wire)
Jul-17-23 11:59AM
Frequency (FREQ) Up 77% on Merger Deal With Korro Bio
(Zacks) -12.66%
Jul-14-23 11:22AM
Why Are Frequency Therapeutics Shares Surging Today
(Benzinga) +77.47%
06:30AM
Korro Bio and Frequency Therapeutics Announce Merger Agreement
(Business Wire)
May-12-23 04:01PM
Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results
(Business Wire) -5.17%
Mar-10-23 07:30AM
Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results
(Business Wire)
Feb-27-23 07:30AM
Frequency Therapeutics to Participate at Upcoming March Investor Conferences
(Business Wire) +5.40%
Feb-13-23 01:55PM
Hearing loss startup to cut more than half of staff in wake of trial failure
(American City Business Journals) -80.54%
11:17AM
Frequency Therapeutics' Lead Hearing Loss Program Flunks, Shifts Focus To Multiple Sclerosis, Shares Plunge
(Benzinga)
08:05AM
Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
(Business Wire)
Dec-19-22 07:30AM
Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program
(Business Wire)
Dec-15-22 07:30AM
Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Companys Second Therapeutic Candidate for Sensorineural Hearing Loss
(Business Wire)
Nov-17-22 07:30AM
Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results
(Business Wire) -10.05%
Nov-08-22 04:05PM
Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results
(Business Wire) -9.51%
Oct-12-22 07:30AM
Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
(Business Wire) +7.47%
Aug-30-22 07:30AM
Frequency Therapeutics to Participate in September Investor and Medical Conferences
(Business Wire)
Aug-09-22 04:05PM
Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results
(Business Wire) -11.11% +9.00%
Jun-24-22 09:03AM
Frequency Therapeutics (NASDAQ:FREQ) one-year losses have grown faster than shareholder returns have fallen, but the stock jumps 41% this past week
(Simply Wall St.) -7.59%
May-25-22 12:00PM
Frequency Therapeutics, Inc. (FREQ) Upgraded to Buy: What Does It Mean for the Stock?
(Zacks)
May-18-22 07:30AM
Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference
(Business Wire) -9.02%
May-04-22 04:30PM
Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results
(Business Wire)
Apr-22-22 07:30AM
Frequency Therapeutics to Participate in B. Riley Securities Neuro & Ophthalmology Investor Conference
(Business Wire)
Apr-08-22 05:00PM
Frequency Exchange Corp. Virtually Closes the Market
(PR Newswire) -8.82%
Mar-15-22 07:30AM
Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results
(Business Wire) +15.29%
Mar-10-22 06:35PM
Poseida Therapeutics, Inc. (PSTX) Beats Q4 Earnings and Revenue Estimates
(Zacks) -13.70%
Feb-28-22 07:30AM
Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences
(Business Wire)
Jan-14-22 05:43AM
One Frequency Therapeutics, Inc. (NASDAQ:FREQ) insider upped their stake in the previous year
(Simply Wall St.)
Jan-04-22 07:30AM
Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference
(Business Wire)
Dec-28-21 02:38AM
Destra Investment Trust Buys ThredUp Inc, Etsy Inc, Riskified, Sells , , 2U Inc
(GuruFocus.com) +5.28%
Dec-09-21 01:18PM
Frequency Therapeutics' Hearing Loss Candidate Shows Improved Speech Perception In Noise
(Benzinga)
07:30AM
Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise
(Business Wire)
Nov-30-21 05:53AM
Frequency Therapeutics (NASDAQ:FREQ) investors are sitting on a loss of 81% if they invested a year ago
(Simply Wall St.)
Nov-15-21 12:25PM
Frequency Therapeutics, Inc. (FREQ) Reports Q3 Loss, Lags Revenue Estimates
(Zacks)
07:30AM
Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results
(Business Wire)
Nov-09-21 07:30AM
Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis
(Business Wire)
Nov-08-21 03:00PM
Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for
(Zacks)
Oct-27-21 07:30AM
Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program
(Business Wire)
Oct-21-21 07:30AM
Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint
(Business Wire)
Oct-01-21 08:23AM
Do Insiders Own Lots Of Shares In Frequency Therapeutics, Inc. (NASDAQ:FREQ)?
(Simply Wall St.)
Sep-22-21 11:18AM
Frequency Therapeutics' New Data Of Hearing Loss Candidate Fails To Impress Investors
(Benzinga)
07:30AM
Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points
(Business Wire)
Sep-08-21 07:30AM
Frequency Therapeutics to Present at Upcoming Investor Conferences
(Business Wire)
Aug-30-21 05:10PM
Lifshitz Law Firm, P.C. Announces Investigations of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Frequency Therapeutics, Inc. (NasdaqGS: FREQ), RLX Technology Inc. (NYSE: RLX), and Washington Prime Group, Inc. (NYSE: WPG)
(ACCESSWIRE)
Aug-12-21 04:06PM
Moore Kuehn, PLLC Encourages Investors of FREQ to Contact Law Firm
(Newsfile)
08:45AM
Frequency Therapeutics, Inc. (FREQ) Reports Q2 Loss, Tops Revenue Estimates
(Zacks)
07:30AM
Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results
(Business Wire)
Aug-04-21 03:00PM
Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for
(Zacks)
Aug-02-21 03:05PM
CLASS ACTION UPDATE for JRVR, FREQ and QFIN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
(ACCESSWIRE)
02:30PM
Final Deadline Alert: Frequency Therapeutics, Inc. (FREQ) Class Action and Last Chance for Investors to Actively Participate - Bronstein, Gewirtz & Grossman, LLC
(ACCESSWIRE)
12:30PM
SHAREHOLDER ALERT: FREQ RKT QFIN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
(ACCESSWIRE)
12:30PM
FINAL DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
(ACCESSWIRE)
11:00AM
FREQ Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Frequency Therapeutics, Inc. (FREQ) Shareholders of Class Action and Lead Plaintiff Deadline: August 2, 2021
(ACCESSWIRE)
10:00AM
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FREQ, RKT and BZ
(ACCESSWIRE)
09:16AM
FREQ Final Deadline Today: Rosen, National Trial Lawyers, Encourages Frequency Therapeutics, Inc. Investors to Secure Counsel Before Important August 2 Deadline in Securities Class Action - FREQ
(Newsfile)
09:09AM
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
(Newsfile)
05:50AM
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FREQ, RLX and DIDI
(ACCESSWIRE)
Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Agarwal VineetChief Financial OfficerNov 11 '24Option Exercise11.688009,344800Nov 12 07:40 PM
Agarwal VineetChief Financial OfficerNov 11 '24Sale70.0080056,0000Nov 12 07:40 PM
Agarwal VineetOfficerNov 11 '24Proposed Sale70.0080056,000Nov 12 08:28 AM
Agarwal VineetChief Financial OfficerOct 17 '24Option Exercise11.9910,216122,46810,216Oct 18 07:43 PM
Agarwal VineetChief Financial OfficerOct 17 '24Sale78.2610,216799,5270Oct 18 07:43 PM
Agarwal VineetOfficerOct 17 '24Proposed Sale78.2610,216799,527Oct 17 04:22 PM
Colletti SteveFormer OfficerOct 16 '24Proposed Sale88.6713,8211,225,450Oct 16 01:05 PM
Colletti SteveFormer OfficerAug 30 '24Proposed Sale49.2410,303507,326Aug 30 05:28 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Theme Settings • Contact • Blog • Help • Privacy • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.